Evidence map›Paper›PMID 39996899›Full record

Observational studyCurrent oncology (Toronto, Ont.)2025

Compartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome.

Abhishek Mahajan, Ujjwal Agarwal, Renuka M Ashtekar, Nivedita Chakrabarty, Richa Vaish, Vijay Maruti Patil, Vanita Noronha, Nandini Menon, Vasundhara Smriti, Jai Prakash Agarwal and 9 more

Abstract readObservational Study
In one paragraph

Observational study in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Considerations on multiportal compartmental approach extended to the temporal fossa.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Abhishek MahajanDepartment of Imaging, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool L7 8YA, UK.ORCID 0000-0001-6606-6537
Ujjwal AgarwalDepartment of Radiodiagnosis and Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400012, India.
Renuka M AshtekarDepartment of Radiodiagnosis and Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400012, India.
Nivedita ChakrabartyTata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Parel, Mumbai 400012, India.ORCID 0000-0003-4569-0693
Richa VaishDepartment of Head and Neck Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Vijay Maruti PatilDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Vanita NoronhaDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Nandini MenonDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Vasundhara SmritiDepartment of Radiodiagnosis and Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400012, India.
Jai Prakash AgarwalDepartment of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Sarbani Ghosh-LaskarDepartment of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Anil K D'CruzDepartment of Head and Neck Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Pankaj ChaturvediDepartment of Head and Neck Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Prathamesh PaiDepartment of Head and Neck Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Asawari PatilDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.ORCID 0000-0002-8203-986X
Munita BalDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Swapnil RaneDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Neha MittalDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.
Kumar PrabhashDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400094, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccording to the 8th edition of the American Joint Committee on Cancer (AJCC), involvement of the masticator space and infratemporal fossa (ITF) in oral cancers indicates advanced disease (T4b), which is often considered unresectable. Previous studies have shown that the extent of ITF involvement influences management and outcomes. Therefore, to optimize management, T4b disease should be subclassified based on ITF involvement. Notably, infranotch disease has a more favorable prognosis compared to supranotch disease. Our study also observed that certain subsets of high anterior retroantral ITF involvement may be operable with favorable clinical outcomes. This study aims to derive a new image-based compartmentalization of high ITF involvement and assess its impact on the management and outcomes of oral head and neck squamous cell carcinoma (HNSCC) patients with high ITF involvement. MATERIALS AND

methodsThis retrospective observational study included 154 non-metastatic, upfront unresectable locally advanced HNSCC patients who were fit for induction neoadjuvant chemotherapy (NACT). ITF involvement was classified into distinct compartments, and detailed staging of the primary tumor (T) and regional nodes (Ns) was performed. Clinical data, including patient demographics, treatment received, and follow-up notes, were documented. Prognosis was assessed using survival metrics: event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). The ITF was categorized into the following compartments: compartment 1 (low ITF: medial pterygoid), compartment 2 (anterior high ITF: retroantral fat), compartment 3 (posterior high ITF), including 3a (paramandibular compartment: paramandibular fat/temporalis), 3b (muscle compartment: lateral pterygoid), and 3c (Perineural compartment: pterygopalatine fossa and pterygomaxillary fissure).

resultsOf the 154 cases, 142 (92%) were classified as T4b, with 63 (40.9%) having high ITF involvement and 79 (55.6%) having low ITF involvement. Twelve cases had T4a disease, which was deemed unresectable due to extensive nodal involvement. Subcompartmentalization of the 63 high ITF cases revealed 26 (41.2%) with compartment 2 involvement, 17 (26.9%) with compartment 3a involvement, 11 (17.4%) with compartment 3b involvement, and 9 (14%) with compartment 3c involvement. Disease progression following NACT was significantly higher in compartment 3c, which showed a poor response (

conclusionsBaseline imaging plays a critical role in guiding individualized treatment and predicting clinical outcomes. Low ITF involvement and disease limited to the high retroantral fat compartment exhibit similar clinical outcomes. Among the posterior high ITF compartments, involvement of the pterygopalatine fossa and pterygomaxillary fissure (compartment 3c) is associated with the worst prognosis and poor response to chemotherapy. Subcompartmentalization of ITF involvement provides valuable prognostic information to tailor treatment strategies.

Indexed as

Mouth NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeAJCC 8thCTHNSCCHNSCC stagingimaginginfratemporal fossaoral cancerTNM

Identifiers

PMID39996899
PMCPMC11854881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.